| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/15/2005 | WO2005084707A1 Method of utilizing organic cation transporter oct3-related molecule for treating mental diseases such as depression, anxiety neurosis, drug addiction and the like |
| 09/15/2005 | WO2005084690A1 Use of enhanced water to improve blood sugar management |
| 09/15/2005 | WO2005084681A1 Composition for increasing levels of hormones and a method for preparation of said composition |
| 09/15/2005 | WO2005084671A2 Combination of voriconazole and an antifungal cyp2c19 inhibitor |
| 09/15/2005 | WO2005084665A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof |
| 09/15/2005 | WO2005084654A2 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
| 09/15/2005 | WO2005084649A1 Stable capsule preparation |
| 09/15/2005 | WO2005084462A2 Nanoscale and supersaturated solutions of mineral or trace elements and a method for production of nanoparticles mixtures of nanoparticles, nanoscale solutions and general supersaturated solutions |
| 09/15/2005 | WO2005084444A1 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/15/2005 | WO2005084230A2 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 09/15/2005 | WO2005060709A3 Methods of use of probiotic bifidobacteria for companion animals |
| 09/15/2005 | WO2005058308A3 Treatment for alzheimer's disease and related conditions |
| 09/15/2005 | WO2005054430A3 Hepatitis c virus inhibitors |
| 09/15/2005 | WO2005054198A3 Therapeutics use of pyridinium compounds to modulate naadp activity |
| 09/15/2005 | WO2005032521A3 Non-flammable topical anesthetic liquid aerosols |
| 09/15/2005 | WO2005020900A3 Delivery of a therapeutic agent in a formulation for reduced toxicity |
| 09/15/2005 | WO2005014777A3 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 09/15/2005 | WO2005001022A3 Methods and compositions for enhancing immune response |
| 09/15/2005 | WO2005000210A3 Synthesis of high molecular weight iron-saccharidic complexes |
| 09/15/2005 | WO2004069168A3 Novel antiherpes drug combinations |
| 09/15/2005 | WO2003000844A3 Protein modification and maintenance molecules |
| 09/15/2005 | WO2002048388A3 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 09/15/2005 | US20050204412 Artery- and vein-specific proteins and uses therefor |
| 09/15/2005 | US20050203282 For screening of agonists and antagonists of receptor which may have advantageous pharmaceutical or diagnostical properties; for identification of patients who may present genetic disorders induced by inactive receptor |
| 09/15/2005 | US20050203190 Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| 09/15/2005 | US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release |
| 09/15/2005 | US20050203169 Administering angiotensin converting enzyme; hypertension, diabetes, cardiovascular disease, cancer, gastroenterologic disease neurologic disease |
| 09/15/2005 | US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease |
| 09/15/2005 | US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 09/15/2005 | US20050203124 Compounds for the sustained reduction of body weight |
| 09/15/2005 | US20050203113 Compounds and method for the treatment of overactive bladder |
| 09/15/2005 | US20050203106 Viricide against herpes virus; 3-(2-Fluoropyridin-4-yl)-2-phenyl-7-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine; chemical synthesis |
| 09/15/2005 | US20050203100 Administering acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine (JP-1302); cognition activators, drug abuse, alcoholism, cigarette smoking cessation, schizophrenia, Tourette*s syndrome, epilepsy, psychosis; sexual, psychological, obsessive-compulsive, or nervous system disorders; psychiatry |
| 09/15/2005 | US20050203098 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 09/15/2005 | US20050203082 Administering with a carbamoylating agent such as BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] and CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea]) to treat neoplastic disorders, such as glioblastoma multiforme; anticarcinogenic and antitumor agents; side effect reduction; brain cancer |
| 09/15/2005 | US20050203072 Administering a synergistic mixture of a substituted-pyrazole p38-kinase inhibitor, and an aldosterone antagonist or a diuretic; hypotensitve agents; congestive heart failure; antiarrhythmia, anticoagulant, and antiischemic, and antiinflammatory agents; urogenital, kidney, and brain disorders |
| 09/15/2005 | US20050203068 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 09/15/2005 | US20050203059 Methods and compositions for treatment of ischemia |
| 09/15/2005 | US20050203052 Antiinflammatory agents; antiarthritic agents; inflammatory resporatory disorders; antidiabetic agents |
| 09/15/2005 | US20050203030 Novel effectors of dipeptidyl peptidase IV |
| 09/15/2005 | US20050203006 Novel lipopeptides as antibacterial agents |
| 09/15/2005 | US20050202559 Cancer treatment by metabolic modulations |
| 09/15/2005 | US20050202548 Mammalian enzymatic polypeptide for use as tool in designing drugs which prevent and treat hypercholesterolemia, hyperlipemia, arteriosclerosis, parasitic infection, cell proliferative and vascular diseases |
| 09/15/2005 | US20050202474 Phosphodiesterases |
| 09/15/2005 | US20050202411 Preparing biopsy of tumorous tissue and monitoring chemosensitivity to anticarcinogenic agents; antitumor agents |
| 09/15/2005 | US20050202410 Precise efficacy assay methods for active agents inlcluding chemotherapeutic agents |
| 09/15/2005 | US20050202394 Organ arrest, protection, preservation and recovery |
| 09/15/2005 | US20050202110 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent |
| 09/15/2005 | US20050202101 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| 09/15/2005 | US20050202088 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof |
| 09/15/2005 | US20050202085 Enclosing a unit dose of aspirin in an enclosure having indications and a twist off cap, and a nutritional supplement of calcium |
| 09/15/2005 | US20050202083 Storage stable tablets of fosinopril sodium |
| 09/15/2005 | US20050202080 Mixing the salt or free base of the active pharmaceutical ingredient, tannic acid, and an anti-clumping agent to form a powder tannate salt complex; adding a liquid to the powder mixture to form a moistened blend; forming tablet, capsule or other solid dosage forms |
| 09/15/2005 | US20050202074 Method of administering liposomal encapsulated taxane |
| 09/15/2005 | US20050202032 Use of neglected target tissue antigens in modulation of immune responses |
| 09/15/2005 | US20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| 09/15/2005 | US20050202016 Polypeptide; an amino acid sequence of the family of tumour-suppressing genes related to the gene for the p53 protein; isolated nucleic acid sequences coding for the proteins |
| 09/15/2005 | US20050202011 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| 09/15/2005 | US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 09/15/2005 | US20050202007 Determining a P-selectin activity in a biological sample of the subject,increased P-selectin activity in the sample indicates a procoagulant state in the subject |
| 09/15/2005 | US20050201989 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha |
| 09/15/2005 | US20050201987 Porous carrier of ceramics or glass and pyrrolidone on the carrier for composites and bonding to carrier |
| 09/15/2005 | US20050201980 Method for short-term and long-term drug dosimetry |
| 09/15/2005 | US20050201979 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders |
| 09/15/2005 | US20050201978 Comprising lectin coupled to an immunogeniciety modifier, pokeweed mitogen and with a coating of polyoxyethylene glycol; inhibit isoclass immunoglobulin switching; side effet reduction; antitumor, -carcinogenisis and -metastasis agents; bactericides; fungicide;antiprotazoa agents; side effect reduction |
| 09/15/2005 | US20050201973 Therapeutic supramolecules |
| 09/15/2005 | US20050201955 Use of compatible solutes for inhibiting the release of ceramides |
| 09/15/2005 | US20050201938 Method for selectively inhibiting ghrelin action |
| 09/15/2005 | US20050201934 Binding peptides for carcinoembryonic antigen (CEA) |
| 09/15/2005 | US20050201932 Drug delivery using Polymeric immunoglobulin receptor (pIgR) which when cleaved has a stalk region which remains attached to the cell and a secretory component (SC) which exists in an organ of interest in several forms |
| 09/15/2005 | CA2558813A1 Pharmaceutical composition comprising cxcr3 inhibitor |
| 09/15/2005 | CA2558715A1 Process for inhibiting cell proliferation |
| 09/15/2005 | CA2558263A1 Nanocell drug delivery system |
| 09/15/2005 | CA2558183A1 Use of enhanced water to improve blood sugar management |
| 09/15/2005 | CA2558056A1 Treatment of spinal conditions |
| 09/15/2005 | CA2557643A1 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
| 09/15/2005 | CA2557634A1 Stable capsule preparation |
| 09/15/2005 | CA2557571A1 Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients |
| 09/15/2005 | CA2556380A1 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
| 09/15/2005 | CA2555612A1 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/14/2005 | EP1574219A2 Method of inhibiting fibrosis with a somatostatin agonist |
| 09/14/2005 | EP1574215A1 Solid drug for oral use |
| 09/14/2005 | EP1574212A1 Prevention and treatment of androgen-deprivation induced hot flashes, decreased lean muscle mass, loss of libido or erectile dysfunction |
| 09/14/2005 | EP1574209A1 Device and method for treating ophthalmic diseases |
| 09/14/2005 | EP1573067A2 Methods for identifying therapeutic agents of atherosclerotic plaque lesions |
| 09/14/2005 | EP1573045A2 Heart failure gene determination and therapeutic screening |
| 09/14/2005 | EP1573039A2 Compositions and methods for diagnosing and treating mood disorders |
| 09/14/2005 | EP1573031A2 Androgen regulated nucleic acid molecules and encoded proteins |
| 09/14/2005 | EP1573028A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 09/14/2005 | EP1573025A2 Crystallized structure of type iv collagen nc1 domain hexamer |
| 09/14/2005 | EP1572939A2 Her-2 receptor tyrosine kinase molecules and uses thereof |
| 09/14/2005 | EP1572905A2 Cancer-linked gene as target for chemotherapy |
| 09/14/2005 | EP1572892A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 09/14/2005 | EP1572891A2 Bone anti-resorptive compounds |
| 09/14/2005 | EP1572890A2 Slc7s as modifies of the p53 pathway and methods of use |
| 09/14/2005 | EP1572877A2 Drug metabolizing enzymes |
| 09/14/2005 | EP1572875A2 Receptors and membrane-associated proteins |
| 09/14/2005 | EP1572874A2 Antibodies that immunospecifically bind to trail receptors |
| 09/14/2005 | EP1572872A2 Igs as modifiers of the p53 pathway and methods of use |
| 09/14/2005 | EP1572871A2 T1r3 a novel taste receptor |